These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35263200)

  • 1. RNA-seq and integrated network analysis reveals the hub genes and key pathway of paclitaxel inhibition on Adriamycin resistant diffuse large B cell lymphoma cells.
    Hong H; Luo B; Qin Y; Li S; Peng Z
    Bioengineered; 2022 Mar; 13(3):7607-7621. PubMed ID: 35263200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirt1 gene confers Adriamycin resistance in DLBCL via activating the PCG-1α mitochondrial metabolic pathway.
    Zhou Z; Ma D; Li P; Wang P; Liu P; Wei D; Wang J; Qin Z; Fang Q; Wang J
    Aging (Albany NY); 2020 Jun; 12(12):11364-11385. PubMed ID: 32570218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FASN contributes to ADM resistance of diffuse large B-cell lymphoma by inhibiting ferroptosis via nf-κB/STAT3/GPX4 axis.
    Zhong X; Zhang W; Zhang W; Yu N; Li W; Song X
    Cancer Biol Ther; 2024 Dec; 25(1):2403197. PubMed ID: 39345091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map database.
    Luo B; Gu YY; Wang XD; Chen G; Peng ZG
    Pathol Res Pract; 2018 Nov; 214(11):1854-1867. PubMed ID: 30244948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Qing K; Jin Z; Xu Z; Wang W; Li X; Zhang Y; Wang L; Zhu H; Xiang R; Wu S; Li R; Jiang G; Xue K; Li J
    Chemotherapy; 2022; 67(1):12-23. PubMed ID: 34844236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
    Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
    J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
    Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
    Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma.
    Maxwell SA; Cherry EM; Bayless KJ
    Leuk Lymphoma; 2011 May; 52(5):849-64. PubMed ID: 21323512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway.
    Wang S; Sun L
    Bioengineered; 2021 Dec; 12(1):8296-8308. PubMed ID: 34565287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects and mechanisms of 1,25(OH)2D3 in the Pfeiffer diffuse large B lymphoma cell line.
    Han J; Tang Y; Zhong M; Wu W
    Mol Med Rep; 2019 Dec; 20(6):5064-5074. PubMed ID: 31638226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of taxane-containing chemotherapy of doxorubicin-resistant diffuse large B-cell lymphoma.
    Wu L; Wang J; Li Y; Zuo L; Zhang Z; Ouyang J; Fan J; Li H
    Anticancer Drugs; 2014 Aug; 25(7):826-31. PubMed ID: 24423982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.
    Li J; Huang Y; Zhang Y; Wen J; Chen Y; Wang L; Jiang P; Hu J
    Med Oncol; 2021 Feb; 38(4):33. PubMed ID: 33629212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
    Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X
    Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide DNA methylation and RNA-seq analyses identify genes and pathways associated with doxorubicin resistance in a canine diffuse large B-cell lymphoma cell line.
    Hsu CH; Tomiyasu H; Liao CH; Lin CS
    PLoS One; 2021; 16(5):e0250013. PubMed ID: 33961622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
    Yang JM; Jang JY; Jeon YK; Paik JH
    J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
    BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen.
    Song YH; Zhong MZ; Gan PP; Yi PY; Tang YH; Liu YP; Jiang JQ; Li L
    Tumour Biol; 2014 Dec; 35(12):11809-17. PubMed ID: 25344211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen.
    Maxwell SA; Li Z; Jaya D; Ballard S; Ferrell J; Fu H
    J Biol Chem; 2009 Aug; 284(33):22379-22389. PubMed ID: 19525224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAK1 is a druggable kinase for diffuse large B-cell lymphoma.
    Wu Y; Yang R; Ming Y; Xu Y; Chen H; Yao M; Chen X; Mao R; Fan Y
    Cell Biochem Funct; 2019 Apr; 37(3):153-160. PubMed ID: 30907011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.